High-yields and extended serum half-life of human interferon α2b expressed in tobacco cells as arabinogalactan-protein fusions

Biotechnology and Bioengineering

Volumn 97, Issue 5, 2007, Pages 997-1008

  Xu, Jianfeng ^a,b   Tan, Li ^a   Goodrum, Kenneth J ^a   Kieliszewski, Marcia J ^a  

^a OHIO UNIVERSITY   (United States)

^b Department of Biological and Environmental Engineering   (United States)

Author keywords

Arabinogalactan protein; Half life; Hydroxyproline O glycosylation; Interferon 2b; Plant cell culture; Recombinant protein

Indexed keywords

BIOACTIVITY; GENE EXPRESSION; POLYETHYLENE GLYCOLS; PROTEINS;

ARABINOGALACTAN-PROTEIN; HYDROXYPROLINE-O-GLYCOSYLATION; RECOMBINANT PROTEINS;

PLANT CELL CULTURE;

ALPHA2B INTERFERON; ARABINOGALACTAN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; MOUSE; NONHUMAN; PROTEIN CARBOHYDRATE INTERACTION; SINGLE DRUG DOSE; TOBACCO;

CELLS, CULTURED; CLONING, MOLECULAR; GENETIC ENHANCEMENT; HALF-LIFE; HUMANS; INTERFERON ALFA-2A; METABOLIC CLEARANCE RATE; MUCOPROTEINS; PLANT PROTEINS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TOBACCO;

MUS; NICOTIANA TABACUM;

EID: 34547590342     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21407     Document Type: Article

References (55)

1. Adolf GR, Kalsner I, Ahorn H, Maurer-Fogy I, Cantell K. 1991. Natural human interferon-α2 is O-glycosylated. Biochem J 276:511-518.
2. An G. 1985. High efficiency transformation of cultured tobacco cells. Plant Physiol 79:568-570.
3. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W. 2001. Rational design of a potent, long-acting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α2 for the treatment of hepatitis C. Bioconjug Chem 12:195-202.
4. Bardor M, Cabrera G, Rudd PM, Dwek RA, Cremata JA, Lerouge , P. 2006. Analytical strategies to investigate plant N-glycan profiles in the context of plant-made pharmaceuticals. Current Opin Struct Biol 16:576-583.
5. Borner GHH, Sherrier DJ, Stevens TJ, Arkins IT, Dupree P. 2002. Prediction of glycosylphosphatidylinositol (GPI)-anchored proteins in Arabidopsis: A genomic analysis. Plant Physiol 129:486-499.
6. Brecker L, Wicklein D, Moll H, Fuchs EC, Becker W-M., Petersen A. 2005. Structural and immunological properties of arabinogalactan polysaccharides from pollen of timothy grass Iphleum pratense L. Carbohyd Res 340:657-663.
7. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima G, Chang S, Chu H, Mukku V, Canova-Davis E, Somers T, Cronin M, Winkler M, Wells JA. 1996. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 271:21969-21977.
8. DeFrees S, Wang ZG, Xing R, Scott AE, Wang J, Zopf D, Gouty DL, Sjoberg ER, Panneerselvam K, Brinkman-Van Der Linden ECM, Bayer RJ, Tarp MA, Clausen H, 2006. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16:833-843.
9. De Loose M, Gheysen G, Tire C, Gielen J, Villarroel R, Genetello C, Van Montagu M, Depicker A, Inze D. 1991. The extensin signal peptide allows secretion of a heterologous protein from protoplasts. Gene 99:95-100.
10. Doran PM. 2006. Foreign protein degradation and instability in plants and plant tissue cultures Trends Biotechnol 24(9):426-432.
11. Doran PM. 2000. Foreign protein production in plant tissue cultures. Curr Opin Biotechnol 11:199-204.
12. Eylar EH., 1966. On the biological role of glycoproteins. J Theor Biol 10:89-113.
13. Fischer R, Emans N, Schuster F, Hellwig S, Drossard J. 1999. Towards molecular farming in the future: using plant cell suspension cultures as bioreactors. Biotechnol Appl Biochem 30:109-112.
14. Garcia-Casado G, Sanchez-Monge R, Chrispeels MJ, Armentia A, Salcedo G, Gomez L. 1996. Role of complex asparagine-linked glycans in the allergenicity of plant glycoproteins. Glycobiology 6:471-477.
15. Giddings G, Allison G, Brooks D, Carter A. 2000. Transgenic plants as factories for biopharmaceuticals. Nature Biotechnol 18:1151-1155.
16. Gutterman JU., 1994. Cytokine therapeutics: Lessons from interferon α. Proc Natl Acad Sci USA 91:1198-1205.
17. Harris JM, Martin NE, Modi M. 2001. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 40:539-551.
18. Harris JM, Chess RB. 2003. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
19. Held MA, Tan L, Kamyab A, Hare M, Shpak E, Kieliszewksi MJ., 2004. Di-isodityrosine is the intermolecular cross-link of isodityrosine-rich extensin analogs cross-linked in vitro. J Biol Chem 279:55474-55482.
20. Hellwig S, Drossard J, Twyman RM, Fischer R. 2004. Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 22:1415-1422.
21. Holsters M, de Waele D, Depicker A, Messens E, van Montagu M, Schell J. 1978. Transfection and transformation of Agrobacterium tumefaciens. Mol Gen Genet 163:181-187.
22. Jentoft N. 1990. Why are proteins glycosylated? Trends Biochem Sci 15:291-294.
23. Kieliszewski MJ, Lamport DTA. 1994. Extensin: Repetitive motifs, functional sites, posttranslational codes and phylogeny. Plant J 5:157-172.
24. Kieliszewski MJ, Shpak E. 2000. Synthetic genes for the elucidation of glycosylation codes for arabinogalactan-proteins and other hydroxyproline-rich glycoproteins. Cell Mol Life Sci 58:1386-1398.
25. Kieliszewski MJ, Xu JF. 2006. Methods of producing peptides/proteins and peptides/proteins produced thereby. U.S. Patent, No. US-20060026719.
26. Knox JP, Linstead PJ, Peart J, Cooper C, Roberts K. 1991. Developmentally regulated epitopes of cell surface arabinogalactan proteins and their relation to root tissue pattern formation Plant J 1:317-326.
27. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
28. Leonard R, Petersen B-O., Himly M, Kaar W, Wopfner N, Kolarich D, van Ree R, Ebner C, Duus J, Ferreira F, Altmann F. 2005. Two novel types of O-glycans on the mugwort pollen allergen Art v 1 and their role in antibody binding. J Biol Chem 280:7932-7940.
29. Motose H, Sugiyama M, Fukuda H. 2004. A proteoglycan mediates inductive interaction during plant vascular development. Nature 429:873-878.
30. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JXH, Garcia A, Moody G, Zaritskaya LS, Sung C. 2002. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-α fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303:540-548.
31. Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL, Parry TJ, 2002. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol 456:149-158.
32. Ramon J, Saez V, Baez R, Aldana R, Hardy E., 2005. PEGylated interferon-alpha 2b: A branched 40K polyethylene glycol derivative. Pharm Res 22:1374-1386.
33. Roberts MJ, Bentley MD, Harris JM., 2002. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 54:459-476.
34. Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN., 2005. A long-acting, highly potent interferon α-2 conjugate created using site-specific. PEGylation Bioconjug Chem 16:200-207.
35. Schellekens H., 2002. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1:457-462.
36. Schenk RU, Hildebrandt AC., 1972. Medium and techniques for induction and growth of monocotyledonous and dicotyledonous plant cell cultures. Can J Bot 50:199-204.
37. Sharp JM, Doran PM., 2001. Characterization of monoclonal antibody fragments produced by plant cells. Biotechnol Bioeng 73(5):338-346.
38. 7-interferon- α2. Proc Natl Acad Sci USA 98:1212-1217.
39. Shpak E., 2001. Synthetic genes for the elucidation of hydroxyproline-O-glycosylation codes Ph.D. thesis. Athens, OH: Ohio University.
40. Shpak E, Barbar E, Leykam IF, Kieliszewski MJ., 2001. Contiguous hydroxyproline residues direct hydroxyproline arabinosylation in Nicotiana tabacum. J Biol Chem 276:11272-11278.
41. Shpak E, Leykam JF, Kieliszewski MJ., 1999. Synthetic genes for glycoprotein design and the elucidation of hydroxyproline-o-glycosylation code. Proc Natl Acad Sci USA 96(26):14736-14741.
42. Staub JM, Garcia B, Graves J, Hajdukiewicz PTJ, Hunter P, Nehra N, Paradkar V, Schlittlet M, Carroll JA, Spatola L, Ward D, Ye G, Russell D., 2000. A. High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Biotechnol 18:333-338.
43. Tan L., 2003. O-glycosylation motifs in arabinogalactan-proteins. Ph.D. thesis. Athens, OH: Ohio University.
44. Tan L, Leykam JF, Kieliszewski MJ., 2003. Glycosylation motifs that direct arabinogalactan addition to arabinogalactan-proteins. Plant Physiol 132:1362-1369.
45. Tan L, Qiu F, Lamport DTA, Kieliszewski MJ., 2004. Structure of a hydroxyproline-arabinogalactan polysaccharide from repetitive Ala-Hyp expressed in transgenic Nicotiana tabacum. J Biol Chem 279:b 13156-13165.
46. Tsubery H, Mironchik M, Fridkin M, Shechter Y., 2004. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J Biol Chem 279:38118-38124.
47. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF., 2002. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 54:547-570.
48. Walsh G., 2003. Biopharmaceutical benchmarks-2003. Nat Biotechnol 21:865-870.
49. Wilson IB, Harthill JE, Mullin NP, Ashford DA, Altmann F., 1998. Core alpha1,3-fucose is a key part of the epitope recognized by antibodies reacting against plant N-linked oligosaccharides and is present in a wide variety of plant extracts. Glycobiology 8:651-661.
50. Wileman TE. 1991. Properties of asparaginase-dextran conjugates. Adv Drug Deliv Rev 6:167-180.
51. Wu X, Li X, Zeng Y, Zheng Q, Wu S. 2006. Site-directed PEGylation of human basic fibroblast growth factor. Protein Exp Purif 38:24-27.
52. Xu J, Shpak E, Gu T, Moo-Young M, Kieliszewski M. 2005. Production of recombinant plant gum with tobacco cell culture in bioreactor and gum characterization. Biotechnol Bioeng 90:578-588.
53. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobayashi K, Okamoto T, Mukai Y, Shimizu T, Nakagawa S, Nakagawa S, Mayumi T. 2003. Site-specific PEGylation of lysine-deficient TNF-α with full bioactivity. Nat Biotechnol 21:546-552.
54. Yates EA, Valdor JF, Haslam SM, Morris HR, Dell A, Mackie W, Knox JP. 1996, Characterization of carbohydrate structural features recognized by anti-arabinogalactan-protein monoclonal antibodies. Glycobiology 6:131-139.
55. Zhao ZD, Tan L, Showalter AM, Lamport DTA, Kieliszewski MJ. 2002. Tomato LeAGP-1 arabinogalactan-protein purified from transgenic tobacco corroborates the Hyp contiguity hypothesis. Plant J 31(4):431-444.